Loss of, or mutations in Rb has been the most frequently observed change in cells resistant to CDK4/6 inhibitors regardless of the cancer type (Herrera-Abreu et al. 2016; Taylor-Harding et al. 2015; Bollard et al. 2017). This evidence concerns the gene RB1 and cancer.